Amyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Amyloidosis Clinical Trials Market Report Overview
The Amyloidosis clinical trial report provides a comprehensive understanding of the osteoporosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East & Africa · South & Central America |
Key Countries | · The US
· Italy · The UK · France · Japan · Germany · Spain · China · Canada · The Netherlands |
Key Sponsor Types | · Institution
· Company · Government |
Leading Sponsors | · Pfizer Inc
· Alnylam Pharmaceuticals Inc · GSK plc · Johnson & Johnson · Ionis Pharmaceuticals Inc · BridgeBio Pharma Inc · Bristol-Myers Squibb Co · Prothena Corp Plc · Takeda Pharmaceutical Co Ltd · AstraZeneca Plc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Amyloidosis Clinical Trials Market Segmentation by Regions
A few of the key regions in the Amyloidosis clinical trials market are Asia-Pacific, Europe, North America, the Middle East & Africa, and South & Central America. North America dominates the market as of August 2023.
As of August 2023, in a country-wise analysis, the US has the highest number of Amyloidosis clinical trials, followed by Italy, the UK, France, Japan, Germany, Spain, China, Canada, and the Netherlands.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Italy has the highest proportion of Amyloidosis to Metabolic Disorders clinical trials as of August 2023. Moreover, most of the clinical trials are conducted in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey has the highest proportion of Amyloidosis to Metabolic Disorders clinical trials as of August 2023. Out of all the clinical trials conducted in the E7 countries, the majority are in China.
Amyloidosis Clinical Trials Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the Amyloidosis Clinical Trials Market
Amyloidosis Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Amyloidosis clinical trials market are institution, company, and the government. Out of them, the institution sponsor type dominates the market.
Amyloidosis Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
Buy the Full Report for More Sponsor Type Insights into Amyloidosis Clinical Trials Market
Amyloidosis Clinical Trials Market - Competitive Landscape
The leading sponsors in the Amyloidosis clinical trials market are Pfizer Inc., Alnylam Pharmaceuticals Inc., GSK plc, Johnson & Johnson, Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc, Bristol-Myers Squibb Co, Prothena Corp Plc, Takeda Pharmaceutical Co Ltd, and AstraZeneca Plc. Pfizer Inc. led the Amyloidosis clinical trials market in August 2023.
Amyloidosis Clinical Trials Market Analysis by Sponsors, 2023 (%)
Buy Full Report to Know More About the Leading Sponsors in the Amyloidosis Clinical Trials Market
Segments Covered in the Report
Amyloidosis Clinical Trials Regional Outlook (2023)
- North America
- Europe
- Asia-Pacific
- Middle East & Africa
- South & Central America
Amyloidosis Clinical Trials Country Outlook (2023)
- The US
- Italy
- The UK
- France
- Japan
- Germany
- Spain
- China
- Canada
- The Netherlands
Amyloidosis Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials about the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key investment strategies.
- Helps in identifying time-saving and cost-efficient locations to conduct clinical trials.
- Provides top-level analysis of the global clinical trials market to help in identifying key business opportunities.
- Helps in understanding trial count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country level.
Alnylam Pharmaceuticals Inc
GSK plc
Johnson & Johnson
Ionis Pharmaceuticals Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
Prothena Corp Plc
Takeda Pharmaceutical Co Ltd
AstraZeneca Plc
Table of Contents
Table
Figures
Frequently asked questions
-
Which is the leading region in the Amyloidosis clinical trials market in August 2023?
North America is the leading region in the Amyloidosis clinical trials market as of August 2023.
-
Which is the leading country in the Amyloidosis clinical trials market in August 2023?
The US is the leading country in the Amyloidosis clinical trials market as of August 2023.
-
Which is the leading sponsor type in the Amyloidosis clinical trials market in August 2023?
The institution sponsor type is the leading sponsor type in the Amyloidosis clinical trials market as of August 2023.
-
Who are the leading sponsors in the Amyloidosis clinical trials market?
The leading sponsors in the Amyloidosis clinical trials market are Pfizer Inc, Alnylam Pharmaceuticals Inc., GSK plc, Johnson & Johnson, Ionis Pharmaceuticals Inc, BridgeBio Pharma Inc, Bristol-Myers Squibb Co, Prothena Corp Plc, Takeda Pharmaceutical Co Ltd, and AstraZeneca Plc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.